Literature DB >> 23506188

Stage determination in sleeping sickness: comparison of two cell counting and two parasite detection techniques.

Dieudonné Mumba Ngoyi1, Joris Menten, Pati Patient Pyana, Philippe Büscher, Veerle Lejon.   

Abstract

OBJECTIVES: Diagnosis of the neurological stage of human African trypanosomiasis is performed by examination of cerebrospinal fluid (CSF) for the presence of trypanosomes and numbers of white blood cells (WBC). Both CSF parameters are also used to assess treatment outcome during follow-up. In view of the importance of CSF examination, and the practical problems encountered with it, we compared the sensitivity of two trypanosome concentration techniques and the repeatability of two cell counting methods, as well as occurrence of systematic differences between them.
METHODS: Patients were recruited at Dipumba hospital, in Mbuji-Mayi in the Democratic Republic of the Congo. In 94 CSF samples, trypanosome detection was performed with modified single centrifugation (MSC) and double centrifugation (DC). On 189 CSF samples with ≤30 cells/μl, cell counting was performed in duplicate in a Fuchs-Rosenthal counting chamber and in a disposable Uriglass counting chamber.
RESULTS: Modified single centrifugation detected trypanosomes in significantly (P < 0.0001) more patients (85) than DC (46). Cell counts did not differ systematically in the two methods. Variability in the differences between duplicate cell counts was significantly higher (P = 0.002) in Uriglass (SD of differences 2.03) than in Fuchs-Rosenthal (SD of differences 1.62).
CONCLUSIONS: For analysis of CSF in the context of sleeping sickness stage determination and follow-up after treatment, we strongly recommend the MSC for parasite detection and the application of disposable counting chambers. When the first cell count is ≤20 cells/μl, we recommend repeating the counting procedure on the same CSF specimen and taking the average of both countings.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23506188     DOI: 10.1111/tmi.12102

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  6 in total

1.  Interleukin (IL)-6 and IL-10 Are Up Regulated in Late Stage Trypanosoma brucei rhodesiense Sleeping Sickness.

Authors:  Charles D Kato; Vincent P Alibu; Ann Nanteza; Claire M Mugasa; Enock Matovu
Journal:  PLoS Negl Trop Dis       Date:  2015-06-19

2.  Plasma cytokine profiles associated with rhodesiense sleeping sickness and falciparum malaria co-infection in North Eastern Uganda.

Authors:  Julius Nsubuga; Charles Drago Kato; Ann Nanteza; Enock Matovu; Vincent Pius Alibu
Journal:  Allergy Asthma Clin Immunol       Date:  2019-10-30       Impact factor: 3.406

3.  Cost-effectiveness modelling to optimise active screening strategy for gambiense human African trypanosomiasis in endemic areas of the Democratic Republic of Congo.

Authors:  Christopher N Davis; Kat S Rock; Marina Antillón; Erick Mwamba Miaka; Matt J Keeling
Journal:  BMC Med       Date:  2021-04-01       Impact factor: 8.775

4.  Plasma Neuron-Specific Enolase is not a reliable biomarker for staging Trypanosoma brucei rhodesiense sleeping sickness patients.

Authors:  Charles D Kato; Dorothy Twesigye; Vincent P Alibu; Ann Nanteza; Julius Nsubuga; Claire M Mugasa; Enock Matovu
Journal:  BMC Res Notes       Date:  2022-03-07

5.  Cerebrospinal Fluid-Derived Microvesicles From Sleeping Sickness Patients Alter Protein Expression in Human Astrocytes.

Authors:  Vito Dozio; Veerle Lejon; Dieudonné Mumba Ngoyi; Philippe Büscher; Jean-Charles Sanchez; Natalia Tiberti
Journal:  Front Cell Infect Microbiol       Date:  2019-11-20       Impact factor: 5.293

6.  Neopterin and CXCL-13 in Diagnosis and Follow-Up of Trypanosoma brucei gambiense Sleeping Sickness: Lessons from the Field in Angola.

Authors:  Julien Bonnet; Philippe Vignoles; Natalia Tiberti; Vatunga Gedeão; Alexandre Hainard; Natacha Turck; Theophile Josenando; Joseph M Ndung'u; Jean-Charles Sanchez; Bertrand Courtioux; Sylvie Bisser
Journal:  Biomed Res Int       Date:  2019-11-23       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.